FranÃ§ois Vergez

List of Publications by Year
in descending order

45 papers	1,945 citations	394421 19 h-index	276875 41 g-index
48 all docs	48 docs citations	48 times ranked	3706 citing authors

#	Article	IF	Citations
1	CD158k and PD-1 expressions define heterogeneous subtypes of Sezary syndrome. Blood Advances, 2022, 6, 1813-1825.	5.2	6
2	Accurate classification of plasma cell dyscrasias is achieved by combining artificial intelligence and flow cytometry. British Journal of Haematology, 2022, 196, 1175-1183.	2.5	6
3	Genomic landscape of hyperleukocytic acute myeloid leukemia. Blood Cancer Journal, 2022, 12, 4.	6.2	7
4	Spectrum of Kidney Disorders Associated with T-Cell Immunoclones. Journal of Clinical Medicine, 2022, 11, 604.	2.4	2
5	â€œAccelerated phaseâ€•chronic lymphocytic leukemia: Still an intermediate risk disease in the era of targeted therapies. Hematological Oncology, 2022, 40, 805-808.	1.7	0
6	Eyeâ€catching spindleâ€shaped mast cells without sinister significance. British Journal of Haematology, 2021, 192, 798-798.	2.5	0
7	Major rise of a chronic lymphoid leukemia clone during the course of COVIDâ€19. International Journal of Laboratory Hematology, 2021, 43, e82-e83.	1.3	7
8	Unsupervised Flow Cytometry Analysis Allows for an Accurate Identification of Minimal Residual Disease Assessment in Acute Myeloid Leukemia. Cancers, 2021, 13, 629.	3.7	23
9	Identification of circulating regulatory T lymphocytes with membrane markers â€" a new multiparameter flow cytometry protocol. Folia Histochemica Et Cytobiologica, 2021, 59, 75-85.	1.5	1
10	Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells. Nature Communications, 2021, 12, 422.	12.8	36
11	From Immune Dysregulations to Therapeutic Perspectives in Myelodysplastic Syndromes: A Review. Diagnostics, 2021, 11, 1982.	2.6	6
12	Genomics of Hyperleukocytic Acute Myeloid Leukemia. Blood, 2021, 138, 1294-1294.	1.4	0
13	Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia. Nature Cancer, 2021, 2, 1204-1223.	13.2	42
14	Real-World Outcomes of Patients with Refractory or Relapsed FLT3-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study. Cancers, 2020, 12, 2044.	3.7	8
15	CD34+CD38â^'CD123+ Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents. Cancers, 2020, 12, 1174.	3.7	7
16	Large granular lymphocytosis during quizartinib therapy. British Journal of Haematology, 2020, 189, 7-7.	2.5	2
17	Dendrogenin A Synergizes with Cytarabine to Kill Acute Myeloid Leukemia Cells In Vitro and In Vivo. Cancers, 2020, 12, 1725.	3.7	13
18	Extracellular ATP and CD39 Activate cAMP-Mediated Mitochondrial Stress Response to Promote Cytarabine Resistance in Acute Myeloid Leukemia. Cancer Discovery, 2020, 10, 1544-1565.	9.4	39

#	Article	IF	Citations
19	Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse–Bordeaux DATAML Registry Study. Cancers, 2020, 12, 773.	3.7	11
20	Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute myeloid leukemia. European Journal of Haematology, 2019, 102, 131-142.	2.2	57
21	Bendamustine plus rituximab for indolent B–cell lymphoma of renal significance. American Journal of Hematology, 2018, 93, 356-362.	4.1	6
22	Dexamethasone in hyperleukocytic acute myeloid leukemia. Haematologica, 2018, 103, 988-998.	3.5	49
23	Hydroxyurea prior to intensive chemotherapy in AML with moderate leukocytosis. Leukemia Research, 2018, 75, 7-10.	0.8	1
24	Assessment of tumor-infiltrating TCRV**γ**9V**δ**2**γδ**lymphocyte abundance by deconvolution of human cancers microarrays. OncoImmunology, 2017, 6, e1284723.	4.6	134
25	Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism. Cancer Discovery, 2017, 7, 716-735.	9.4	582
26	Asymptomatic circulating T-cell clone cause renal polymorphic inflammatory fibrosis. Clinical and Experimental Nephrology, 2017, 21, 781-786.	1.6	3
27	Dendrogenin A drives LXR to trigger lethal autophagy in cancers. Nature Communications, 2017, 8, 1903.	12.8	84
28	Long non-coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients. Haematologica, 2017, 102, 1718-1726.	3.5	32
29	Signaling mechanisms that regulate ex vivo survival of human acute myeloid leukemia initiating cells. Blood Cancer Journal, 2017, 7, 636.	6.2	7
30	Impact of obesity in favorable–risk AML patients receiving intensive chemotherapy. American Journal of Hematology, 2016, 91, 193-198.	4.1	22
31	Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells. Blood, 2016, 127, 882-892.	1.4	108
32	Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia. Journal of Experimental Medicine, 2016, 213, 483-497.	8.5	68
33	Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies. Oncotarget, 2016, 7, 85937-85947.	1.8	9
34	Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with *FLT3-ITD* or *c-KIT* Mutations. Molecular Cancer Therapeutics, 2015, 14, 2364-2373.	4.1	52
35	Hyperferritinemia at diagnosis predicts relapse and overall survival in younger AML patients with intermediate-risk cytogenetics. Leukemia Research, 2015, 39, 818-821.	0.8	24
36	CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia. Oncotarget, 2015, 6, 38061-38078.	1.8	20

#	Article	IF	Citations
37	Rituximab–cyclophosphamide–dexamethasone is highly effective in patients with monoclonal <scp>I</scp>g deposit–related glomerulopathy and indolent non‐<scp>H</scp>odgkin lymphomas. American Journal of Hematology, 2014, 89, 969-973.	4.1	9
38	Initial absolute lymphocyte count as a prognostic factor for outcome in acute myeloid leukemia. Leukemia and Lymphoma, 2014, 55, 855-862.	1.3	16
39	The ROS/SUMO Axis Contributes to the Response of Acute Myeloid Leukemia Cells to Chemotherapeutic Drugs. Cell Reports, 2014, 7, 1815-1823.	6.4	86
40	Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription. Blood, 2013, 122, 738-748.	1.4	53
41	Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. Blood, 2013, 121, 2618-2626.	1.4	100
42	Class I Phosphoinositide 3-Kinases in Normal and Pathologic Hematopoietic Cells. Current Topics in Microbiology and Immunology, 2012, 362, 163-184.	1.1	2
43	High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica, 2011, 96, 1792-1798.	3.5	164
44	Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience. Oncotarget, 2011, 2, 850-861.	1.8	29
45	Canine Reference Intervals for Coagulation Markers Using the STA Satellite® and the STA-R Evolution® Analyzers. Journal of Veterinary Diagnostic Investigation, 2010, 22, 690-695.	1.1	10